

Characterisation of the pathogenic effect of missense mutations in proteins via machine learning

Qisheng Pan^{1,2}, Georgina Becerra Parra¹, Stephanie Portelli^{1,2}, Thanh Binh Nguyen^{1,2}, David B. Ascher^{1,2}

¹School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane Queensland 4072, Australia

²Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne Victoria 3004, Australia

 Qisheng Pan


 QishengPan

qisheng.pan@uq.net.au

BACKGROUND

- Proteins control most fundamental cellular and biological processes, but small changes in the protein sequence can **alter these tightly regulated functions**, and may be associated with a **wide range of diseases**.
- It is time-consuming to experimentally elucidate the effects of all possible missense variants.
- Pioneering “gold standard” methods to quantify the effect of these variants rely primarily on **gene/protein sequences**, showing **limited performance** and a **bias on the deleterious variants**.
- To improve the capability of characterising missense mutations, we aimed to develop next-generation *in-silico* tools by leveraging protein information from **both sequence and structure**.


- Graph-based signatures:** atomic pair patterns




- Nodes:** atoms with different pharmacophores
- Edges:** atom pairs within a certain distance cutoff

METHODOLOGY


Data curation



Feature generation




Machine learning



CASE 1: mutations leading to cancer

- Over 50% of cancers are associated with the missense mutations in tumour suppressor protein p53.
- p53 plays a crucial role in DNA damage-induced activation by repairing erroneous replication and activating cellular apoptosis.



- Non-functional mutations** mainly distributed in the **DNA-binding domain** and sporadically distributed in the **Oligomerization domain**.

Blind test


| Method | MCC | Recall | Precision |
|-----------|------|--------|-----------|
| our Model | 0.88 | 0.99 | 0.96 |
| TP53_PROF | 0.88 | 0.91 | 0.90 |
| Envision | 0.60 | 0.95 | 0.89 |
| VARITY | 0.72 | 0.91 | 0.96 |
| SIFT | 0.46 | 0.59 | 0.98 |
| PolyPhen2 | 0.42 | 0.54 | 0.98 |

Clinical validation

| Method | MCC | Recall | Precision |
|-----------|------|--------|-----------|
| our Model | 0.83 | 1.00 | 0.93 |
| TP53_PROF | 0.83 | 1.00 | 0.93 |
| Envision | 0.58 | 0.96 | 0.88 |
| VARITY | 0.78 | 0.98 | 0.93 |
| SIFT | 0.58 | 0.75 | 0.98 |
| PolyPhen2 | 0.47 | 0.64 | 0.97 |

- Our model showed **robust performance** on both blind test and clinical validation.

MCC: Matthew's Correlation Coefficient / Recall: True positive rate / Precision: 1 - False discovery rate




- Feature interpretation reveals that intact p53 function is strongly reliant on **experimental residue activity**, the **number of polar-polar atom pairs within 6 Å**, and the **change of protein stability upon mutation**

CASE 2: mutations leading to Alzheimer's Disease



- Alzheimer's Disease (AD) is one of the most common neurodegenerative disease.

Mutation distribution of a multi-gene dataset



- 680 missense mutations of 21 proteins related to AD were collected from different databases.
- Mutation with different phenotypes were **highly imbalanced** in protein level.

Machine learning analysis



- By tuning the **sample weights** during the training process, we improved the ability of identify pathogenic mutations into **protein-specific level**.

- Feature interpretation presented **both the sequenced and structural residue environment**, **residue interaction**, and the **properties of mutant** are essential to the risk of Alzheimer's Disease.

CONCLUSION

- By integrating structure-based features, our models **accurately characterise** the oncogenic effects of **all possible missense mutations** in p53 and identify missense mutations increasing risks of Alzheimer's Disease, with a comparable performance to state-of-the-art methods.
- The mutation analysis of p53 offers **clinical diagnostic utility**, which is crucial for patient monitoring, and the development of personalised cancer treatment.
- Our multi-gene studies on AD not only provide clinically relevant tools, but also a better foundation to understand **the protein sequence-structure-function-pathogenicity relationships**.